Hello Readers,
Sam Altman, CEO of OpenAI, and his husband Oliver Mulherin are backing Preventive, a biotech startup aiming to use embryo gene editing to eliminate hereditary diseases before birth a step filled with both hope and controversy.
What Is Preventive Trying to Do?
Preventive, based in San Francisco, has raised $30 million from investors including Altman and Brian Armstrong. The company plans to use CRISPR-style editing to fix harmful genetic mutations in embryos, with the goal of preventing severe inherited diseases before a child is born.
Why Altman and His Husband Are Involved
Mulherin is motivated by helping families avoid genetic illnesses, and Altman supports this vision. Armstrong notes that over 300 million people globally live with genetic diseases, arguing that early embryo editing may be more effective than later medical treatments.
The Ethical and Scientific Debate
Embryo editing is banned in many countries because of safety risks and unknown long-term effects. Critics worry about unintended mutations, unequal access, and the possibility of sliding toward “designer babies.” These concerns raise deeper questions about consent and who decides what genes should be changed.
Regulatory Hurdles & Research Strategy
With strict laws in the U.S. and U.K., Preventive is considering regions with more flexible regulations, such as the UAE. For now, the company is doing preclinical research and promises to publish all findings before attempting any human trials.
Risks & Bigger Picture
Gene edits could affect future generations, raising scientific and ethical uncertainty. Oversight, fairness, and past controversies make the path even more complex.
Why This Matters to You
If successful, this technology could prevent hereditary diseases, transform medicine, and push society to rethink genetic ethics and global regulations.
Final Thoughts
Altman’s support signals a bold attempt to stop genetic disease before birth—but one that comes with significant ethical and scientific challenges.
Complied by Namrata Bhelsekar
